文献速递淋巴瘤

纳武利尤单抗联合维布妥昔单抗治疗复发/难治性原发纵隔大B细胞淋巴瘤:3年随访

Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up.
PubMed 文献 · Blood Adv · 2023-01-01

在复发/难治性原发纵隔大B细胞淋巴瘤(R/R PMBL)患者中开展的1/2期开放标签多中心CheckMate 436研究3年随访显示,纳武利尤单抗联合维布妥昔单抗的客观缓解率为73.3%,中位无进展生存期26.0个月,中位总生存期未达到,未观察到新的安全性信号。

要点

  • 纳武利尤单抗联合维布妥昔单抗治疗R/R PMBL的客观缓解率为73.3%,中位缓解时间1.3个月。
  • 中位无进展生存期26.0个月,中位总生存期未达到,24个月PFS率55.5%、OS率75.5%。
  • 最常见的3/4级治疗相关不良事件为中性粒细胞减少,3年随访未观察到新的安全性信号。

核心结论

  • 3年随访显示纳武利尤单抗联合维布妥昔单抗在R/R PMBL中具有长期疗效,且未观察到新的安全性信号。

研究设计与样本

  • 1/2期开放标签、多中心CheckMate 436研究(NCT02581631)的3年随访,共29例患者接受纳武利尤单抗联合维布妥昔单抗治疗。
  • 入组患者年龄≥15岁,既往接受过高剂量化疗联合自体造血细胞移植或≥2种多药化疗,ECOG体能状态评分0-1,CD30表达≥1%。
  • 治疗方案为纳武利尤单抗240 mg联合维布妥昔单抗1.8 mg/kg,每3周一次,直至疾病进展或不可接受的毒性。
  • 主要终点为客观缓解率,次要终点包括完全缓解率、缓解持续时间、无进展生存期和总生存期。

主要发现

  • 最终数据库锁定时(2022年3月30日),29例患者接受治疗,中位随访39.6个月。
  • 研究者评估的客观缓解率为73.3%,中位缓解时间为1.3个月(范围1.1-4.8)。
  • 中位无进展生存期为26.0个月,中位总生存期未达到。
  • 24个月无进展生存率为55.5%(95%CI 32.0-73.8),24个月总生存率为75.5%(95%CI 55.4-87.5)。
  • 12例患者接受了巩固性造血细胞移植,100天完全缓解率为100.0%。

关键数值与推荐

  • 最常见的3/4级治疗相关不良事件为中性粒细胞减少。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Patients with relapsed/refractory primary mediastinal large B-cell lymphoma (R/R PMBL) have poor responses to salvage therapy. Nivolumab and brentuximab vedotin (BV) showed promising early efficacy in patients with R/R PMBL in the phase 1/2 open-label, multicenter CheckMate 436 study; we report safety and efficacy findings from the 3-year follow-up. Patients who were eligible were aged ≥15 years with R/R PMBL previously treated with either high-dose chemotherapy plus autologous hematopoietic cell transplantation (HCT) or ≥2 prior multiagent chemotherapies, and had Eastern Cooperative Oncology Group performance status scores of 0 to 1 and CD30 expression of ≥1%. Patients were treated with nivolumab 240 mg and BV 1.8 mg/kg once every 3 weeks until disease progression or unacceptable toxicity. Primary end point was objective response rate (ORR); secondary end points included complete response rate, duration of response, progression-free survival (PFS), and overall survival (OS). Safety was monitored throughout. At final database lock (30 March 2022), 29 patients had received nivolumab plus BV; median follow-up was 39.6 months. Investigator-assessed ORR was 73.3%; median time to response was 1.3 months (range, 1.1-4.8). Median PFS was 26.0 months; median OS was not reached. PFS and OS rates at 24 months were 55.5% (95% confidence interval [CI], 32.0-73.8) and 75.5% (95% CI, 55.4-87.5), respectively. The most frequently occurring grade 3/4 treatment-related adverse event was neutropenia. Consolidative HCT was received by 12 patients, with a 100-day complete response rate of 100.0%. This 3-year follow-up showed long-term efficacy for nivolumab plus BV in R/R PMBL, with no new safety signals. This trial was registered at www.clinicaltrials.gov as #NCT02581631.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Zinzani PL, Santoro A, Gritti G, et al. Nivolumab combined with brentuximab vedotin for R/R primary mediastinal large B-cell lymphoma: a 3-year follow-up. Blood Adv. 2023. PMID: 37352266. doi:10.1182/bloodadvances.2023010254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。